The Isocitrate Dehydrogenase Inhibitors Market size is expected to grow at an annual average of 4% during 2022-2028. Isocitrate dehydrogenase (IDH) is an enzyme involved in the conversion of isocitrate to -ketoglutarate in the tricarboxylic acid cycle. In the two-step reaction, IDH plays an important role in catalyzing the reversible conversion of isocitrate to alpha-ketoglutarate and CO2. IDH inhibitors are classified as IDH1 inhibitors, IDH2 inhibitors, or IDH1/IDH2 inhibitors. Agios discovered the first IDH1 inhibitor, AGI-5918, and the IDH2 inhibitor, AGI-6780. Clinical trials are conducted with all IDH inhibitors. IDH is a small molecule protein found primarily in the liver, heart muscle, and skeletal muscle.
(Get 15% Discount on Buying this Report)
A full report of Isocitrate Dehydrogenase Inhibitors Market is available at: https://orionmarketreports.com/isocitrate-dehydrogenase-inhibitors-market/83652/
The following segmentation are covered in this report:
By Application
- FLT3 Inhibitor
- DH Inhibitor
- Hedgehog Pathway Inhibitor
- Others
By Type
- IDH1 Mutant Medullary Malignant Tumor
- IDH2 Mutant Medullary Malignant Tumor
- Others
Company Profile
- Agios Pharmaceuticals
- Bayer
- Daiichi Sankyo Company
- Evotec
- GlaxoSmithKline
- Novartis
The report covers the following objectives:
- Proliferation and maturation of trade in the global Isocitrate Dehydrogenase Inhibitors Market
- The market share of the global Isocitrate Dehydrogenase Inhibitors Market supply and demand ratio, growth revenue, supply chain analysis, and business overview.
- Current and future market trends that are influencing the growth opportunities and growth rate of the Isocitrate Dehydrogenase Inhibitors Market
- Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Isocitrate Dehydrogenase Inhibitors Market
Scope of the report
The research study analyses the Isocitrate Dehydrogenase Inhibitors Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:
Recent developments
- Market overview and growth analysis
- Import and export overview
- Volume analysis
- Current market trends and future outlook
- Market opportunistic and attractive investment segment
Geographic coverage
- North america market size and/or volume
- Latin america market size and/or volume
- Europe market size and/or volume
- Asia-pacific market size and/or volume
- Rest of the world market size and/or volume
Key Questions Answered by Isocitrate Dehydrogenase Inhibitors Market Report
- What was the Isocitrate Dehydrogenase Inhibitors Market size in 2022 and 2028; what are the estimated growth trends and market forecast (2022-2028)
- What will be the CAGR of Market during the forecast period (2022-2028)?
- Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
- Which manufacturer/vendor/players in the Isocitrate Dehydrogenase Inhibitors Market was the market leader in 2022?
- Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.
About us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company name: Orion Market Reports
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
